BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical & Diagnostic

Mabwell Wins NMPA Approval for China’s First Albumin-Fused Long-Acting G-CSF Therapy MAILISHENG

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that Albipagrastim alfa for Injection (trade name...

June 02, 2025 | News

ASP Isotopes and Isotopia Forge Strategic Alliance to Secure Gd-160 Supply for Next-Gen Cancer Radiotherapeutics

ASP Isotopes Inc. (NASDAQ: ASPI) and Isotopia Molecular Imaging Ltd. have entered into a strategic agreement to secure the supply of Gadolinium-160 (Gd-160...

June 02, 2025 | News

Kexing Biopharm’s GB18 Receives IND Approval in China and U.S. for Cancer Cachexia Treatment

Kexing Biopharm (688136.SH) announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) applica...

May 30, 2025 | News

Specialised Therapeutics Secures TGA Approval for SKYTROFA® as Australia’s First Once-Weekly Treatment for Paediatric Growth Hormone Deficiency

Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the Australian registration of SKYTROFA® (lonapegsomatropin)...

May 30, 2025 | News

Thermo Fisher Launches Attune Xenith Flow Cytometer to Deliver More Cellular Insights in Less Time

Researchers can obtain deeper insights from cells with more colors and faster time to results with minimal sample volume Thermo Fisher Scientific Inc., th...

May 30, 2025 | News

Eisai’s DAYVIGO® Approved in China to Treat Insomnia, Targeting Over 170 Million Adults

Eisai Co., Ltd. announced that the in-house-discovered and developed orexin receptor antagonist DAYVIGO® (generic name: lemborexant) has been app...

May 29, 2025 | News

RemeGen’s Telitacicept Approved in China as First Dual-Target Biologic for Generalized Myasthenia Gravis

RemeGen Co., Ltd.(688331.SH / 09995.HK) announced that Telitacicept has officially been approved for marketing in China by the National Medical Produc...

May 28, 2025 | News

UniXell Biotech Initiates China’s First iPSC-Based Cell Therapy Trial for Parkinson’s Disease

Shanghai UniXell Biotechnology Co., Ltd. (UniXell Biotech), a biotech company dedicated to innovative cell therapies, announced the successful first admini...

May 26, 2025 | News

AnnJi Reports Promising Phase 1/2a Results for AJ201 in Rare Neuromuscular Disease SBMA

AnnJi Pharmaceutical Co., Ltd., a clinical-stage Taiwanese biotechnology company focused on addressing unmet medical needs in dermatology, neurology, and r...

May 22, 2025 | News

Minghui Doses First Patient in Phase II Trial of PD-1xVEGF Bispecific and TROP-2 ADC Combo for Advanced NSCLC

Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative therapies in immunology and oncology, announced that ...

May 21, 2025 | News

Antengene and MSD Enter Global Clinical Collaboration to Evaluate ATG-022 and KEYTRUDA® Combo in Solid Tumors

Antengene Corporation Limited , a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercial...

May 21, 2025 | News

BioMed X and Boehringer Ingelheim Launch Global Call for Next-Gen Intraocular Biologics Platform

The BioMed X Institute announced today the launch of a new global call for research proposals in collaboration with Boehringer Ingelhei...

May 21, 2025 | News

Xuanzhu Biopharmaceutical’s Bireociclib (Xuanyuening®) Approved in China, Setting New Benchmark in HR+/HER2- Breast Cancer Treatment

National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market. Bireociclib tablets (trade...

May 19, 2025 | News

InnoCare Pharma Doses First Patient in Phase II/III Trial of Soficitinib for Vitiligo in China

InnoCare Pharma a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has...

May 19, 2025 | News

Stay Connected